Cailing Ma

State Key Laboratory Of Pathogenesis
Ueruemqi, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Bi-A@SR Nanoparticles Enable Tumor-Localized NO Release to Suppress HSP70 and Reverse Chemoresistance.

Bi-A@SR Nanoparticles Enable Tumor-Localized NO Release to Suppress HSP70 and Reverse Chemoresistance.

Journal: Advanced healthcare materials
Published: March 10, 2026

Nanotechnology empowered photodynamic therapy: a paradigm shift from local ablation to systemic immunity.

Nanotechnology empowered photodynamic therapy: a paradigm shift from local ablation to systemic immunity.

Journal: Chemical communications (Cambridge, England)
Published: January 21, 2026

LAG-3-associated CD8+ T-cell dysfunction in the cervical cancer tumor microenvironment.

LAG-3-associated CD8+ T-cell dysfunction in the cervical cancer tumor microenvironment.

Journal: Frontiers in immunology
Published: November 20, 2025

Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer.

Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer.

Journal: International journal of nanomedicine
Published: November 08, 2025

Overcoming chemoresistance via NO-mediated HSP inhibition using hybrid membrane-coated multifunctional nanoplatforms.

Overcoming chemoresistance via NO-mediated HSP inhibition using hybrid membrane-coated multifunctional nanoplatforms.

Journal: Materials today. Bio
Published: August 17, 2025

MIR155HG promotes metastasis and cisplatin resistance of cervical cancer cells by regulating the miR-409-3p and ZEB1 axis.

MIR155HG promotes metastasis and cisplatin resistance of cervical cancer cells by regulating the miR-409-3p and ZEB1 axis.

Journal: Scientific reports
Published: March 27, 2025

Vaginal microbiota changes of persistent human papillomavirus infection after cervical conization.

Vaginal microbiota changes of persistent human papillomavirus infection after cervical conization.

Journal: Frontiers in cellular and infection microbiology
Published: December 16, 2024

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

Journal: Med (New York, N.Y.)
Published: October 22, 2024

The application value of low-risk human papillomavirus testing in cervical cancer prevention and treatment in low- and middle-resource areas.

The application value of low-risk human papillomavirus testing in cervical cancer prevention and treatment in low- and middle-resource areas.

Journal: Public health
Published: April 16, 2024

Trends in high-risk human papillomavirus infection and cervical cytology of women in Karamay City, 2012-2021.

Trends in high-risk human papillomavirus infection and cervical cytology of women in Karamay City, 2012-2021.

Journal: Sexual health
Published: March 14, 2024

The effects of metabolites from three vaginal bacteria on the Syndecan-1 of cervical epithelial cells.

The effects of metabolites from three vaginal bacteria on the Syndecan-1 of cervical epithelial cells.

Journal: Heliyon
Published: January 02, 2024

M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.

M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.

Journal: European journal of medical research
Published: December 23, 2023
Showing 1-12 of 39

Last Updated: 09/26/2026